These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16203059)

  • 21. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.
    Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A
    Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.
    Hausdorff WP; Dagan R; Beckers F; Schuerman L
    Vaccine; 2009 Dec; 27(52):7257-69. PubMed ID: 19833248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
    Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
    Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential.
    Hsieh YC; Lin PY; Chiu CH; Huang YC; Chang KY; Liao CH; Chiu NC; Chuang YC; Chen PY; Chang SC; Liu JW; Yen MY; Wang JH; Liu CY; Lin TY
    Vaccine; 2009 Sep; 27(40):5513-8. PubMed ID: 19615960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive pneumococcal disease in Fiji: clinical syndromes, epidemiology, and the potential impact of pneumococcal conjugate vaccine.
    Russell FM; Carapetis JR; Tikoduadua L; Paeds D; Chandra R; Seduadua A; Satzke C; Pryor J; Buadromo E; Waqatakirewa L; Mulholland EK
    Pediatr Infect Dis J; 2010 Sep; 29(9):870-2. PubMed ID: 20622710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
    Giele C; Moore H; Bayley K; Harrison C; Murphy D; Rooney K; Keil AD; Lehmann D
    Vaccine; 2007 Mar; 25(13):2379-84. PubMed ID: 17064825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
    Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR
    Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal vaccines.
    Ho CF; Lin TY
    Chang Gung Med J; 2005 Nov; 28(11):765-72. PubMed ID: 16422182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
    Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
    Oosterhuis-Kafeja F; Beutels P; Van Damme P
    Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
    Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
    Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.